文献速递核素与放射性配体治疗肿瘤 PET/CT

设计一种具有高肿瘤与健康组织比值的成纤维细胞活化蛋白靶向放射性药物治疗

Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios.
PubMed 文献 · J Nucl Med · 2024-08-01

研究设计了一种靶向成纤维细胞活化蛋白(FAP)的新型放射性药物[177Lu]Lu-FAP8-PEG3-IP-DOTA,在四种小鼠肿瘤模型中评估其摄取、滞留和治疗效果,结果显示对FAP高亲和力、肿瘤高滞留、健康组织摄取低,肿瘤与健康组织比值均超过5倍,肿瘤生长抑制65%-93%,全身毒性轻微或无。

要点

  • FAP8-PEG3-IP-DOTA对FAP的半数抑制浓度为1.6 nM,选择性优于脯氨酰寡肽酶(约14.0 nM)和二肽基肽酶-IV(约860 nM)。
  • SPECT/CT显示在两种实体瘤模型中高滞留,健康组织摄取极低;所有主要器官的肿瘤与健康组织比值均超过5倍。
  • 在四种模型中观察到65%-93%的肿瘤生长抑制,全身毒性轻微或无。

核心结论

  • [177Lu]Lu-FAP8-PEG3-IP-DOTA是用于实体瘤FAPα靶向放射性核素治疗的有前景且安全的候选放射性药物。

研究设计与样本

  • 设计新型FAP靶向放射性药物FAP8-PEG3-IP-DOTA,在KB、HT29、MDA-MB-231和4T1小鼠肿瘤模型中通过放射成像或离体生物分布分析评估[111In]In或[177Lu]Lu-FAP8-PEG3-IP-DOTA的摄取和滞留。
  • 通过监测荷瘤小鼠的肿瘤生长、体重和组织损伤来研究放射治疗效力和总体毒性。

主要发现

  • FAP8-PEG3-IP-DOTA对FAP的半数抑制浓度为1.6 nM,对脯氨酰寡肽酶的半数抑制浓度约为14.0 nM,对二肽基肽酶-IV的半数抑制浓度约为860 nM。
  • SPECT/CT扫描显示在两种不同实体瘤模型中高滞留,健康组织摄取极低。
  • 定量生物分布分析显示所有主要器官的肿瘤与健康组织比值均超过5倍。
  • 活体动物研究显示在全部四种测试模型中肿瘤生长抑制为65%-93%,全身毒性轻微或无。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Because of upregulated expression on cancer-associated fibroblasts, fibroblast activation protein (FAP) has emerged as an attractive biomarker for the imaging and therapy of solid tumors. Although many FAP ligands have already been developed for radiopharmaceutical therapies (RPTs), most suffer from inadequate tumor uptake, insufficient tumor residence times, or off-target accumulation in healthy tissues, suggesting a need for further improvements. Methods: A new FAP-targeted RPT with a novel ligand (FAP8-PEG3-IP-DOTA) was designed by combining the desirable features of several previous ligand-targeted RPTs. Uptake and retention of [111In]In or [177Lu]Lu-FAP8-PEG3-IP-DOTA were assessed in KB, HT29, MDA-MB-231, and 4T1 murine tumor models by radioimaging or ex vivo biodistribution analyses. Radiotherapeutic potencies and gross toxicities were also investigated by monitoring tumor growth, body weight, and tissue damage in tumor-bearing mice. Results: FAP8-PEG3-IP-DOTA exhibited high affinity (half-maximal inhibitory concentration, 1.6 nM) and good selectivity for FAP relative to its closest homologs, prolyl oligopeptidase (half-maximal inhibitory concentration, ∼14.0 nM) and dipeptidyl peptidase-IV (half-maximal inhibitory concentration, ∼860 nM). SPECT/CT scans exhibited high retention in 2 different solid tumor models and minimal uptake in healthy tissues. Quantitative biodistribution analyses revealed tumor-to-healthy-tissue ratios of more than 5 times for all major organs, and live animal studies demonstrated 65%-93% suppression of tumor growth in all 4 models tested, with minimal or no evidence of systemic toxicity. Conclusion: We conclude that [177Lu]Lu-FAP8-PEG3-IP-DOTA constitutes a promising and safe RPT candidate for FAPα-targeted radionuclide therapy of solid tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mukkamala R, Carlson DJ, Miller NK, et al. Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios. J Nucl Med. 2024. PMID: 38871387. doi:10.2967/jnumed.124.267756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。